Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.

This study will be an open-label, randomized, 4-period, single-dose, single-center, crossover study with a William's design in healthy subjects (males). The study will comprise: 1. A screening period of maximum 28 days; 2. Four treatment periods during which subjects will be resident prior to the evening meal the night before dosing with abediterol (Day -1) until at least 48 hours following dosing for collection of PK samples; discharged on the morning of Day 3; and 3. A final safety post-treatment visit within 14 days after the last administration of abediterol. There will be a minimum washout period of 14 days between each treatment period. Each subject will be involved in the study for approximately 12 weeks.